Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw

Katz, Joseph; Gong, Yan; Salmasinia, Donya; Hou, Wei; Burkley, Ben; Ferreira, Pedro Gonçalo; Casanova, Olga Benavent; Langaee, Taimour; Moreb, Jan S.

doi:10.1016/j.ijom.2011.02.002

Cited by 96 publications

(73 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…After a thorough review, five studies were found testing the relationship between CYP2C8 rs1934951 and BONJ risk [11,12,18,19,20]. The article by Katz et al [20] was excluded since the data were not available.…”

Section: Resultsmentioning

confidence: 99%

Association between CYP2C8 (rs1934951) Polymorphism and Bisphosphonate-Related Osteonecrosis of the Jaws in Patients on Bisphosphonate Therapy: A Meta-Analysis

Zhong

Wu²,

Li³

2012

Acta Haematol

View full text Add to dashboard Cite

Aims: Bisphosphonate-related osteonecrosis of the jaws (BONJ) is a severe complication in patients on bisphosphonate therapy. The study was conducted to verify the association between CYP2C8 (rs1934951) polymorphism and BONJ predisposition. Methods: The relative epidemiologic studies were identified in PubMed and Embase to conduct a meta-analysis using STATA. Results: In the pooled analysis with multiple cancer types, patients carrying the CYP2C8 rs1934951 AA or AG genotype showed no significantly increased BONJ susceptibility compared with those carrying the wild GG genotype [dominant: odds ratio (OR) = 2.05, 95% confidence interval (CI) = 0.67–6.29, p = 0.209; recessive: OR = 1.88, 95% CI = 0.23–15.6, p = 0.560; AG vs. GG: OR = 2.07, 95% CI = 0.80–5.32, p = 0.133, and AA vs. GG: OR = 1.34, 95% CI = 0.48–3.74, p = 0.578]. A significant association between AA and AG genotypes of CYP2C8 (rs1934951) and BONJ risk was found in the subgroup analysis of multiple myeloma (dominant: OR = 5.77, 95% CI = 1.21–27.63, p = 0.028; AG vs. GG: OR = 5.02, 95% CI = 2.06–12.23, p = 0.001, and AA vs. GG: OR = 16.23, 95% CI = 1.72–78.7, p = 0.015). Conclusion: The results indicated that AA and AG genotypes of CYP2C8 (rs1934951) might be predictors for multiple myeloma patients at high risk to develop BONJ.

show abstract

Section: Resultsmentioning

confidence: 99%

Association between CYP2C8 (rs1934951) Polymorphism and Bisphosphonate-Related Osteonecrosis of the Jaws in Patients on Bisphosphonate Therapy: A Meta-Analysis

Zhong

Wu²,

Li³

2012

Acta Haematol

View full text Add to dashboard Cite

show abstract

“…Katz et al [93 ] performed a cohort study including 78 patients with myeloma on intravenous bisphosphonate therapy (12 of them developed ONJ). Besides clinical characteristics, they analyzed 10 SNPs from 7 candidate genes and concluded that smoking, type of bisphosphonate and the combined genotype score of COL1A1, RANK, MMP2, OPG and OPN were significantly associated with ONJ.…”

Section: Osteonecrosis Of the Jaw (Onj)mentioning

confidence: 99%

Genetic and acquired factors influencing the effectiveness and toxicity of drug therapy in osteoporosis

López-Delgado¹,

Riancho‐Zarrabeitia²,

Riancho³

2016

Expert Opinion on Drug Metabolism & Toxicology

View full text Add to dashboard Cite

“…this may be caused by underlying odontogenic infection leading to disruption of the continuity of oral epithelium (18). very likely, genetic variations among individuals confer susceptibility or resistance to BRonJ development, since BRonJ occurs only in a certain percentage of BP users (20).…”

Section: Pathogenesis and Clinical Presentationmentioning

confidence: 99%

Bisphosphonate-Related Osteonecrosis of the Jaws. A Severe Side Effect of Bisphosphonate Therapy

Janovska

2012

Acta Med. (Hradec Kralove, Czech Repub.)

View full text Add to dashboard Cite

Summary: Bisphosphonates (BP) are potent inhibitors of bone resorption used mainly in the treatment of metastatic bone disease and osteoporosis. By inhibiting bone resorption, they prevent complications as pathological fracture, pain, tumor-induced hypercalcemia. Even though patient's benefit of BP therapy is huge, various side effects may develop. Bisphosphonate-related osteonecrosis of the jaws (BRonJ) is among the most serious ones. oncologic patients receiving high doses of BP intravenously are at high risk of BRonJ development. BPs impair bone turnover leading to compromised bone healing which may result in the exposure of necrotic bone in the oral cavity frequently following tooth extraction or trauma of the oral mucosa. frank bone exposure may be complicated by secondary infection leading to osteomyelitis development with various symptoms and radiological findings. In the management of BRONJ, conservative therapy aiming to reduce the symptoms plays the main role. in patients with extensive bone involvement resective surgery may lead to complete recovery, provided that the procedure is correctly indicated. Since the treatment of BRONJ is difficult, prevention is the main goal. therefore in high risk patients dental preventive measures should be taken prior to bisphosphonate administration. this requires adequate communication between the prescribing physician, the patient and the dentist.

show abstract

Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw

Cited by 96 publications

References 26 publications

Association between <b><i>CYP2C8</i></b> (rs1934951) Polymorphism and Bisphosphonate-Related Osteonecrosis of the Jaws in Patients on Bisphosphonate Therapy: A Meta-Analysis

Association between <b><i>CYP2C8</i></b> (rs1934951) Polymorphism and Bisphosphonate-Related Osteonecrosis of the Jaws in Patients on Bisphosphonate Therapy: A Meta-Analysis

Genetic and acquired factors influencing the effectiveness and toxicity of drug therapy in osteoporosis

Bisphosphonate-Related Osteonecrosis of the Jaws. A Severe Side Effect of Bisphosphonate Therapy

Contact Info

Product

Resources

About